ION Solutions and Foundation Medicine Enter Into a Preferred Partnership to Deliver Comprehensive Cancer Genomic Profiling Services
Frisco, Texas – (February 12, 2014) – ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United States, today announced the selection of Foundation Medicine as its preferred partner for comprehensive cancer genomic profiling services. Foundation Medicine’s clinical products, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile that complement traditional cancer treatment decision tools and often expands treatment options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor. This relationship will advance the organizations’ shared goals of providing comprehensive cancer diagnostic tools to community oncologists and their patients.<?xml:namespace prefix="o" ns="urn:schemas-microsoft-com:office:office"?>
“Foundation Medicine is the leader in providing comprehensive genomic profiling to the broad oncology community,” said Barry Fortner, President, ION Solutions. “We look forward to our preferred partnership to provide these important tools to community oncologists to help inform treatment decisions and enable precision medicine for their patients.”
“ION Solutions is known for bringing cutting edge technologies to its vast network of community oncologists, and we are very pleased to have been selected as their preferred comprehensive genomic profiling services partner,” commented Kevin Krenitsky, M.D., chief commercial officer and senior vice president, international strategy, Foundation Medicine. “Our mission at Foundation Medicine is to provide broad access to clinical grade and comprehensive genomic sequencing to oncologists at both academic medical centers and community practices, and we believe this partnership will help further these efforts.”
Foundation Medicine has developed the first commercially available targeted sequencing assays using comprehensive, clinical next-generation sequencing to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in solid tumors and hematologic malignancies, as well as many sarcomas and pediatric cancers. Genomic profile results are reported to the oncologist and matched with targeted therapies and clinical trials that may be relevant to each individual patient based on the most recent scientific and medical research. For more information or to order Foundation One and FoundationOne Heme, please visit www.FoundationOne.com.
About ION Solutions and AmerisourceBergen
ION Solutions, a part of AmerisourceBergen Specialty Group, is the largest physician service organization and GPO specializing in the support of community oncology. ION provides technologies, resources and expertise to community-based oncologists to help improve clinical and operational management. Additional information can be found at www.iononline.com. AmerisourceBergen is one of the largest global pharmaceutical services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers ensure patient access to products and better health outcomes. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel. With nearly $100 billion in annualized revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 13,000 people. AmerisourceBergen is ranked #32 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
About Foundation Medicine
Foundation Medicine® (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of Foundation Medicine, Inc.